RT Journal Article SR Electronic T1 Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap JF Journal of Medical Genetics JO J Med Genet FD BMJ Publishing Group Ltd SP 571 OP 577 DO 10.1136/jmedgenet-2018-105472 VO 55 IS 9 A1 Jeanna M McCuaig A1 Tracy L Stockley A1 Patricia Shaw A1 Michael Fung-Kee-Fung A1 Alon D Altman A1 James Bentley A1 Marcus Q Bernardini A1 Beatrice Cormier A1 Hal Hirte A1 Katharina Kieser A1 Andree MacMillan A1 Wendy S Meschino A1 Karen Panabaker A1 Renee Perrier A1 Diane Provencher A1 Kasmintan A Schrader A1 Kimberly Serfas A1 Eva Tomiak A1 Nora Wong A1 Sean S Young A1 Walter Henri Gotlieb A1 Paul Hoskins A1 Raymond H Kim A1 , YR 2018 UL http://jmg.bmj.com/content/55/9/571.abstract AB The landscape of genetic testing in ovarian cancer patients has changed dramatically in recent years. The therapeutic benefits of poly ADP-ribose polymerase (PARP) inhibitors in treatment of BRCA1/2-related ovarian cancers has resulted in an increased demand and urgency for genetic testing results, while technological developments have led to widespread use of multi-gene cancer panels and development of tumour testing protocols. Traditional genetic counselling models are no longer sustainable and must evolve to match the rapid evolution of genetic testing technologies and developments in personalized medicine. Recently, representatives from oncology, clinical genetics, molecular genetics, pathology, and patient advocacy came together to create a national multi-disciplinary Canadian consortium. By aligning stakeholder interests, the BRCA Testing to Treatment (BRCA TtoT) Community of Practice aims to develop a national strategy for tumour and germline BRCA1/2 testing and genetic counselling in women with ovarian cancer. This article serves to provide an overview of the recent evolution of genetic assessment for BRCA1/2-associated gynecologic malignancies and outline a Canadian roadmap to facilitate change, improve genetic testing rates, and ultimately improve outcomes for hereditary ovarian cancer patients and their families.